×

Multiple Sclerosis Drugs Market Report


Company Analysis, History and Future Overview, Global Sales Trends by 2025


Published Date: 2020-02-10   |   Pages: Ongoing   |   Tables: Ongoing   |  Report ID: 8310 |  Industry: Life Science  |   Format : pdf word ppt excel



   Request Sample     Request Customization    Request Methodology
  • SELECT LICENSE TYPE :

  •   Single License
  •  Multi User License
  •  Corporate License



The global multiple sclerosis drugs market is predicted to grow at a healthy rate for the next few years. This could be due to the rising number of clinical drugs and pipeline drugs developed to effectively treat multiple sclerosis. Early in 2020, Ireland’s Trinity College Dublin announced that its scientists have made a new discovery to help develop more effective treatments for autoimmune diseases, including multiple sclerosis. This research focuses on the new role for a specific immune molecule, i.e. IL-17 in a mouse model of multiple sclerosis and potentially in multiple sclerosis.

Investments in Discovery of Advanced Multiple Sclerosis Drugs Likely to Increase Growth

The global demand for multiple sclerosis drugs is anticipated to grow on the back of increasing research and development efforts made to discover new diagnosis and treatment approaches to control the rising prevalence of the central nervous system disorder. Increasing geriatric population at the risk of developing multiple sclerosis could also add to the need for multiple sclerosis drugs. Besides making investments in new multiple sclerosis drug development projects, governments are taking initiatives to increase awareness about the autoimmune disease. This may further contribute to the expansion of the global multiple sclerosis drugs market.

Market Segments

By Route of Administration

 Oral

 Parenteral

By Disease Type

 Progressive-relapsing Multiple Sclerosis

 Secondary-progressive Multiple Sclerosis

 Primary-progressive Multiple Sclerosis

 Relapsing-remitting Multiple Sclerosis

By Distribution Channel

 Online Pharmacies

 Retail Pharmacies and Drug Stores

 Hospital Pharmacies

By Drug Class

 Interferon Beta

 Adrenocorticotropic Hormone

 Sphingosine 1-Phosphate Receptor Modulator

   Corticosteroid

   Mixed Polymer

  Monoclonal Antibody

   Pyrimidine Synthesis Inhibitor

 NF-κB Inhibitor

 Others

Among drug class segments, monoclonal antibody could gain significant growth in future, although interferon beta has already secured a handsome share of the global multiple sclerosis drugs market. Therapeutic monoclonal antibody is used as one of the new tools for molecular targeted approach toward the treatment of multiple sclerosis. Among disease types, relapsing-remitting multiple sclerosis is anticipated to show high growth in the global multiple sclerosis drugs market mainly due to its strong prevalence compared to other types of multiple sclerosis.

Parenteral is one of the most common routes of administration used to deliver multiple sclerosis drugs. Moreover, there has been an increase in the use of injectable multiple sclerosis drugs. All of these factors could contribute to the growth of the parenteral segment. Among distribution channels, retail pharmacies and drug stores are predicted to collect a considerable share of the global multiple sclerosis drugs market because of their wide expansion in key developed and emerging countries.

By Region

world_regions

Promising medical reimbursement policies and increase in the number of multiple sclerosis cases in countries such as the US and Canada are anticipated to help promote the demand for multiple sclerosis drugs in North America. Increasing number of FDA approvals for new multiple sclerosis drugs could be another factor adding to the demand in the North America multiple sclerosis drugs market. Asia Pacific is also expected to create enough opportunities for multiple sclerosis drug manufacturers in future. High investments in the development of therapeutic multiple sclerosis drugs, gradually improving awareness about multiple sclerosis, and the introduction of new products could help Asia Pacific to gain market growth in the coming years.

Players to Launch New Multiple Sclerosis Drugs and Partner with Drug Discovery Companies

Some of the leading players competing in the global multiple sclerosis drugs market are Bayer AG, AbbVie, Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, EMD Serono (Merck KGaA), Sanofi, F. Hoffmann-La Roche Ltd., Actelion Pharmaceuticals (Johnson & Johnson), Celgene Corporation, Biogen, Inc., and Acorda Therapeutics, Inc. Multiple sclerosis drug manufacturers are expected to focus on introducing new and more effective drugs with better results to improve their overall sales growth. Players could also enter into strategic collaborations to strengthen their growth in the global multiple sclerosis drugs market. Early in 2019, Skyhawk Therapeutics and Biogen collaborated to develop innovative small molecule treatments for multiple sclerosis and other neurological diseases.

Life sciences is a wide branch of study that is gradually becoming an integral industry to the global economics. QYR Consulting looks at the steady transformation of the life sciences industry and its impact on the subindustries such as medical care, pharmaceutical, and medical devices. Our team of esteemed analysts have put together reports to analyze the monumental changes life sciences is expected to bring in the overall healthcare industry. These reports identify the exact turning points for the industry and open up a platform for discussing its growth.

QYR Consulting brings to you a structured analysis of the technological advancements so far, vision of the players in the industry, and the strategies they are likely to use to make their mark. The reports dissect various components of the life sciences industry to scrutinize the influential factors. To help the readers make profitable business decisions, analysts have highlighted the lucrative investment areas and upcoming business opportunities.

Request for Table of Contents



  You must accept our privacy policies before submit your requirement




Why QYR Consulting?


We are committed to delivering the best solutions and we offer a 24*7 helpline.


We promise superior quality of authenticated data.


We offer help and advice across varying time zones.


We boast a strong team of experienced analysts.


We have an exhaustive repository of published reports.


Read More

Contact us Directly

USA
 +1 626 428 8800

India
  +91 20 67104444

Beijing
  +86 108 294 5717

For Enquiry : sales@qyrconsulting.com

Request for Tables



  You must accept our privacy policies before submit your requirement




Why QYR Consulting?


We are committed to delivering the best solutions and we offer a 24*7 helpline.


We promise superior quality of authenticated data.


We offer help and advice across varying time zones.


We boast a strong team of experienced analysts.


We have an exhaustive repository of published reports.


Read More

Contact us Directly

USA
 +1 626 428 8800

India
  +91 20 67104444

Beijing
  +86 108 294 5717

For Enquiry : sales@qyrconsulting.com

Request for Figures



  You must accept our privacy policies before submit your requirement




Why QYR Consulting?


We are committed to delivering the best solutions and we offer a 24*7 helpline.


We promise superior quality of authenticated data.


We offer help and advice across varying time zones.


We boast a strong team of experienced analysts.


We have an exhaustive repository of published reports.


Read More

Contact us Directly

USA
 +1 626 428 8800

India
  +91 20 67104444

Beijing
  +86 108 294 5717

For Enquiry : sales@qyrconsulting.com

Reasons to Buy this Report



Fastest report delivery

Fastest report delivery

We have the fastest report delivery service with excellent after-sales support

 

In-depth analysis

In-depth analysis

We provide a comprehensive and in-depth analysis in every report that we sell

 

Large database

Large database

We own large database which will help our clients to get customized and syndicated research reports

 

Accurate data

Accurate data

To offer you accurate data, our seasoned analysts will be available to assist you

 


 

Ask a Question

Get in touch with us to find answers to all your business-related queries for fast results.

 

NOTE - The analysis, thoughts, views, facts, and opinions expressed in this report are of the respective research analysts. QYR Consulting does not necessarily endorse it or it is also not essentially formal views of QYR Consulting.



Multiple Sclerosis Drugs Market Report